Chief Scientific Officer, Caribou Biosciences
Andy leads the research and development team at Caribou Biosciences and has a background developing technologies and bringing innovative products from concept to commercialization. He is a co-founder of Intellia Therapeutics and before joining Caribou, Andy led development teams in sequencing, single-cell genomics and structural proteomics at Fluidigm Corporation. His group pioneered efforts in single-cell RNA-seq, high-throughput HLA typing and analysis of cell-free DNA to track tumor progression. Previously, he held scientific and leadership positions at Thios Pharmaceuticals and Signature Biosciences and was a Wellcome Trust International Postdoctoral Fellow at Stanford University. Andy is an inventor on many patents and patent applications and has authored articles in leading journals describing developments in structural biology, microfluidics, clinical sequencing, single-cell genomics and CRISPR technologies. He received a B.A. in Chemistry and a D.Phil. in Molecular Biophysics, both from the University of Oxford.
In this panel discussion, the gene therapy and cancer immunotherapy pipeline will be discussed. CRISPR-Cas9 developer Caribou Biosciences and immuno-oncology startup Forty Seven Inc. are among the notable panelists.